Generic Drug Patent Law: The Complete Playbook for Market Entry, FDA Strategy, and Competitive Intelligence
Generic drugs account for nearly 90% of all prescriptions dispensed in the United States yet represent only about 20% of […]
April 2019
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded Generics and Why They’re Profitable
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Branded Generics and Why They’re Profitable Read Post »
Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio
Pre-ANDA Litigation Strategy: The Complete Playbook for Building Unbreakable Drug Patent Portfolios For IP counsel, portfolio managers, R&D leads, and
The Post-Exclusivity Event Horizon: Strategic Forecasting of Generic and Biosimilar Entry
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
